Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability or sedation compared to placebo. This suggests CBD may not have meaningful direct anti-seizure or sedative properties on its own, and its clinical benefits in Dravet syndrome and Lennox-Gastaut syndrome likely depend on its pharmacokinetic interaction with clobazam rather than a standalone neurological mechanism.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with concurrent antiepileptic drugs rather than direct effects on neuronal excitability, fundamentally altering how clinicians should interpret its mechanism of action. Understanding that CBD lacks direct cortical effects has important implications for patient selection, dosing strategies, and the rational design of combination antiepileptic regimens, particularly in patients not taking clobazam or other interacting medications.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
⚕️ This well-designed crossover trial challenges a common assumption about CBD’s mechanism in seizure control by demonstrating that CBD does not directly suppress cortical excitability in healthy volunteers, suggesting its clinical benefit in conditions like Dravet syndrome may rely primarily on pharmacokinetic interactions with concurrent medications rather than intrinsic anti-seizure properties. While the study’s use of healthy subjects rather than patients with actual seizure disorders represents an important limitation, and while animal models may reveal different dose-response relationships, the findings underscore the need to reassess how we conceptualize CBD’s role in our treatment algorithms. Clinically, this means we should be cautious about prescribing CBD as monotherapy for seizure disorders and remain attentive to potential drug interactions, particularly with clobazam and other hepatically metabolized anti-seizure medications, when CBD is incorporated into a regimen for patients with epilepsy.
| |